NL-OMON24309
已完成
不适用
The efficacy of the calcimimetic Cinacalcet in persistent Hyperparathyroidsm After Renal Transplantation. A sustained or temporary effect?
Renal Transplant UnitAcademic Medical Center0 个研究点目标入组 20 人待定
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- open label observational study during 8 months in approx 20 renal transplant patients
- 发起方
- Renal Transplant UnitAcademic Medical Center
- 入组人数
- 20
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
/A
研究者
入排标准
入选标准
- •1\. Hypercalciemia more than 2,60 mmol/l;
- •2\. Elevated iPTH plasma levels more than 15 pmol/l;
排除标准
- •1\. Antirejection therapy less than 4 weeks; prior to inclusion;
- •2\. Pregnancy.
结局指标
主要结局
未指定
相似试验
招募中
不适用
Effectiviteit en veiligheid van behandeling met cinacalcet bij patiënten met primaire hyperparathyreoïdie door een MEN-I mutatie.MEN-1Primary HyperparathyroidismPrimair HyperparathyreoidieCinacalcetCaSRNL-OMON23587eiden University Medical CenterDutch MEN-1 Study Group30
进行中（未招募）
不适用
Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation - Cinacalcet in MEN-I PHPTPatients with primary hyperparathyroidism due to a germline mutation in the MEN-1 geneMedDRA version: 12.1Level: LLTClassification code 10036693Term: Primary hyperparathyroidismEUCTR2010-018861-53-NLeiden University Medical Center
已完成
4 期
Efficacy of Cinacalcet in the Control of Primary HyperparathyroidismHyperparathyroidism, PrimaryOsteoporosisNCT02417389Istituto Auxologico Italiano22
已完成
3 期
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular EventsSecondary HyperparathyroidismChronic Kidney DiseaseNCT00345839Amgen3,883
已完成
4 期
Efficacy and safety of treatment with Cinacalcet in patients with Primary Hyperparathyroidism due to a MEN-1 mutatiohyperactive parathyroid glandsprimary hyperparathyroidism1008362410033949NL-OMON34871eids Universitair Medisch Centrum20